Spatial-transcriptomic analysis of tumorimmune microenvironment in AML patients receiving pembrolizumab and decitabine

Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2021
This article has no abstract
Epistemonikos ID: 718490d7e8a040bf05806b2b05b6a225111cea94
First added on: Feb 13, 2025